Skip to main content

Table 9 Efficacy of recent clinical trials with liposomal paclitaxel in mono or combined therapy

From: Nanomedicine review: clinical developments in liposomal applications

References

Years

Phase

Disease

LF

n

Dose

Efficacy

ORR (%)

m-PFS (months)

m-OS (months)

Wang and Zhang (2014)

2014

II

NSCLC

LPTX + carboplatin

27

175 mg/m2

44.4

6

–

Lu et al. (2015)

2015

II

NSCLC

LPTX + gemcitabine + carboplatin

48

3 mg/ml IT + 1000 mg/m2 IV day 1 and 8 + 5 AUC IV day 1 Q3W

81

16.5

23.2

Ahn et al. (2014)

2014

II

NSCLC

Genexol-PM + gemcitabine

 

230 mg/m2 day 1 + 1000 mg/m2 days 1 and 8 IV Q3W

46.5

4

14.8

Hu et al. (2013)a

2013

II

NSCLC

LPTX + cis-platin

63

135 mg PTX/m2 to 175 mg PTX/m2

–

–

–

Ignatiadis et al. (2016)

2016

I

BC

EndoTAG-1 + PTX + fluorouracil + epirubicin + cyclophosphamide

15

22 mg/m2 + 70 mg/m2 IV Q1W + 500 mg/m2 + 100 mg/m2 + 500 mg/m2 Q3W

33

–

–

Awada et al. (2014)

2014

II

TNBC

EndoTAG-1 + PTX

56

22 mg/m2 + 70 mg/m2 Q1W

45

3.7

13.0

EndoTAG-1

58

88 mg/m2 Q1W

25

3

11.9

Lu et al. (2016)

2016

II

AGC

LPTX + capecitabine

34

135 mg/m2 IV day 1 + 2000 mg/m2 PO days 1–14 Q3W

47

6.9

12.5

Xu et al. (2013)

2013

II

MGC

Lipusu®

30

135 mg/m2 IV day 1

47

–

–

Haas et al. (2012)

2012

II

PC

EndoTAG-1 + Gem

50

11 mg/m2

14

4.1

8.1

50

22 mg/m2

14

4.6

8.7

5

44 mg/m2

16

4.4

9.3

Graziani et al. (2017)

2017

II

EOC

PTX–LCN

14

175 mg/m2

–

3

–

Strieth et al. (2013)b

2013

I

HNC

EndoTAG-1

5

1.1 mg PTX/kg

–

–

–

Slingerland et al. (2017)b

2013

II

AC

LEP-ETU

30

175 mg PTX/m2 Q3W

–

–

–

  1. LF liposomal formulation, n number of patients, ORR objective response rate, m-PFS median progression-free survival, m-OS median overall survival, LPTX liposomal paclitaxel, PTX–LCN paclitaxel lipid core nanoparticle, PTX paclitaxel, Gem gemcitabine, LEP-ETU paclitaxel liposomal; Q4W, Q4W, Q3W, Q2W, Q1W, every 4, 3, 2 and 1 weeks, respectively, BC breast cancer, TNBC triple-negative breast cancer, AGC atypical glandular cells, MGC metastatic gastric cancer, PC pancreatic cancer, EOC epithelial ovarian carcinoma, HNC head and neck cancer, AC advance cancer, NSCLC non-small-cell lung carcinoma
  2. aNo results have been proportionated
  3. bOnly the toxicity was mentioned